Comprehensive Palliative Care After Stem Cell Transplantation
Official title: Comprehensive Palliative Care After Stem Cell Transplantation: a Feasability Study
Run by University Hospital, Geneva · NCT07895693 · Data updated 2026-11-12
This study tests whether adding early palliative care after an allogeneic stem cell transplant is feasible and helpful for patients and their families.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 42 (estimated) |
| Sponsor | University Hospital, Geneva Academic / other |
| Locations | 1 site (Geneva, Canton of Geneva) |
| Status | Recruiting |
| Started | August 27, 2026 |
| Main results expected | December 26, 2028 |
| Study ends | December 26, 2028 |
| Registry record updated | October 26, 2026 |
| Trial ID | NCT07895693 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and older undergoing allogeneic HSCT who have a heavy symptom burden, are 65 years or older, or have an intermediate/high/very high disease risk, and who can provide written informed consent and communicate in French.
✕Probably not a fit
Patients without significant symptom burden, those who do not meet the eligibility criteria, or those who prefer not to engage with palliative care may not experience a measurable benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study focuses on adults who have received an allogeneic hematopoietic stem cell transplant. It aims to determine if a systematic, early palliative care approach can be feasibly offered after hospital discharge and whether it is acceptable to patients and caregivers. Eligible participants must have a significant symptom burden, older age, or higher disease risk, and must communicate in French at participating centers in Geneva. The intervention centers on integrated palliative care consultations to address physical, emotional, and practical needs during recovery. The study will assess feasibility metrics such as uptake, acceptability, and potential impacts on quality of life and symptom burden.
Why it matters
Potential benefit: If successful, patients may experience better symptom control, improved quality of life, and reduced caregiver burden during recovery after transplant.
How similar studies have gone: Previous work supports the value of integrating palliative care in cancer treatment, but systematic post-transplant incorporation is less established and is being explored here for feasibility.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years or older. * Undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). * Meet at least one of the following vulnerability criteria: Heavy symptom burden, defined as a score of 3 or higher for at least one symptom on the Edmonton Symptom Assessment System (ESAS); Age 65 years or older; Poor prognosis, defined as a Disease Risk Index (DRI) category of intermediate, high, or very high. * Able to provide written informed consent. * Able to communicate in French and complete study assessments. Exclusion Criteria: * Severe cognitive impairment preventing completion of study questionnaires. * Inability to provide informed consent. * Inability to communicate in French.
Where it's running
-
Geneva University Hospitals
Geneva, Canton of Geneva, Switzerland Recruiting
Study contacts
- Principal investigator: Lisa Hentsch, MD — University Hospital, Geneva
- Study coordinator: Lisa Hentsch, MD
- Email: lisa.hentsch@hug.ch
- Phone: +41 22 372 12 99
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Belumosudil vs. Ruxolitinib for hepatic cGVHD after HSCT
This trial tests whether belumosudil or ruxolitinib works better for hepatic chronic GVHD after a stem cell transplant in people 12 and older.
-
Gastric protection after transplant: switch from PPI to teprenone to see effects on GVHD
This trial tests whether switching from a proton pump inhibitor to teprenone after allogeneic HSCT changes the risk of acute graft-versus-host disease in patients with hematologic cancers.
-
Chlorophyllin to reduce mouth sores before allogeneic stem cell transplant
This phase II study tests whether taking chlorophyllin by mouth can lower the chances and severity of mouth ulcers in patients aged 12–65 undergoing radiation-based conditioning before a first allogeneic stem cell transplant.
-
CMV-specific T cells after CMV reactivation in adults after HSCT
This study tests CMV-specific immune recovery in adults who have their first CMV reactivation after an allogeneic HSCT to see how CMV-specific T cells change over time.
-
Iptacopan for high-risk TA-TMA after HSCT
This study tests whether taking iptacopan by mouth can help patients with high-risk transplantation-associated thrombotic microangiopathy after HSCT fail conventional initial care.
-
High-altitude stem cell and bone marrow transplant registry on the Qinghai-Tibet Plateau
This project will collect clinical data and blood/bone marrow samples from people having hematopoietic stem cell transplants on the Qinghai‑Tibet Plateau to see how high altitude affects transplant outcomes and recovery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.